Anamorelin Benefits: What Studies Report

Anamorelin hydrochloride is an orally active, non-peptide agonist of the growth hormone secretagogue receptor, the same receptor targeted by the hormone ghrelin. Its development programme focused almost entirely on cancer anorexia-cachexia syndrome (CACS), the involuntary loss of body weight and skeletal muscle that accompanies many advanced malignancies. A 2022 drug profile described anamorelin's pharmacology and its clinical development in cancer cachexia (PMID 35274629), and a 2024 review summarised its position in the treatment landscape for cancer anorexia-cachexia syndrome (PMID 38771469).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition or treatment decision. Nothing below is a recommendation, and no outcome described here should be read as something a reader can expect.

How to Read a "Benefits" Page for a Cachexia Drug

Cachexia trials are unusual because the condition has several partly independent dimensions: body weight, body composition, appetite, strength, physical function, inflammation and survival. A compound can move one of these without moving the others. A 2024 systematic review of biomarker endpoints in cancer cachexia clinical trials examined how trials in this field selected and reported their outcome measures (PMID 38783477), which is why the sections below are split by outcome domain rather than merged into a single verdict.

Throughout, the framing is "studied for" and "reported in studies", not "works for". Where published evidence is thin or absent for something people associate with ghrelin agonists, that is stated plainly.

Body Weight: What Studies Report

Body weight is the domain where the literature is most consistent. A 2015 pharmacotherapy review of anamorelin hydrochloride for cancer-anorexia-cachexia in non-small cell lung cancer described weight-related outcomes as a central focus of the compound's development (PMID 25945893). A 2022 profile of anamorelin for cancer cachexia similarly placed weight and body-composition endpoints at the centre of the evidence base (PMID 35274629).

Real-world data have added to the randomised picture. A 2025 observational study examined the effect of anamorelin on body weight in patients with gastric cancer-associated cachexia (PMID 40627291). Observational designs of this kind cannot separate drug effect from concurrent oncology treatment, nutritional support or natural disease fluctuation, so researchers generally treat them as supportive rather than confirmatory.

A 2024 systematic review and network meta-analysis of pharmacotherapy for cancer cachexia compared available agents on efficacy and safety outcomes (PMID 39225556) and is the most useful single reference point for placing anamorelin's weight findings alongside other drug classes studied for the same indication.

Lean Body Mass and Body Composition: What Studies Report

Weight gain in cachexia is only meaningful if it is not purely fat or fluid. Anamorelin's development programme therefore reported lean body mass as a co-primary or key endpoint. The 2015 review of anamorelin hydrochloride in NSCLC cancer-anorexia-cachexia discussed lean body mass among the endpoints that defined the compound's clinical profile (PMID 25945893), and the 2022 drug profile covered the same body-composition focus (PMID 35274629).

Lean mass overlaps with, but is not the same as, sarcopenia. A 2025 review of sarcopenia in gastrointestinal cancers addressed muscle loss and its management in that population, including pharmacological approaches (PMID 41206817). Readers should note that an increase in a measured compartment such as lean body mass is a surrogate; whether it translates into function is treated separately below because the trial literature treated it separately.

Appetite and Anorexia Symptoms: What Studies Report

Because anamorelin acts at the ghrelin receptor, appetite-related endpoints were an expected part of the programme. The 2024 review of anamorelin for cancer anorexia-cachexia syndrome described appetite and anorexia-related symptom outcomes within its summary of the clinical evidence (PMID 38771469). A 2016 overview of clinical results in cachexia therapeutics placed appetite-directed agents in the broader context of what had and had not succeeded in the field (PMID 26974316).

Appetite endpoints in oncology are usually patient-reported questionnaire scores rather than measured food intake, which is one reason reviewers have been cautious about equating symptom-score movement with nutritional improvement (PMID 38783477).

Grip Strength and Physical Function: Where Evidence Was Weaker

Handgrip strength is the domain where commentary has been most sceptical. A 2017 opinion review titled around the question of what comes after anamorelin examined the limitations of the existing evidence and what the field needed next (PMID 28957883). The 2024 review of anamorelin in cancer anorexia-cachexia syndrome also discussed the gap between body-composition endpoints and functional endpoints (PMID 38771469).

In plain terms: the published record does not support a statement that anamorelin improved muscle strength or physical performance. Reviewers have repeatedly flagged this as the unresolved part of the picture (PMID 28957883).

Quality of Life and Survival: What Studies Report

Survival and global quality of life are the endpoints that matter most clinically and are the hardest to move in advanced cancer. A 2015 review of cancer cachexia trials discussed the difficulty of demonstrating hard clinical benefit in this population (PMID 26435290), and the 2024 network meta-analysis of cancer cachexia pharmacotherapy compared agents across efficacy and safety outcomes without resolving the question for any single drug (PMID 39225556).

A 2022 Japanese-language commentary on future prospects in cancer cachexia discussed where the field was heading after anamorelin's availability (PMID 35851337). Taken together with the 2017 "what is next" review (PMID 28957883), the consistent theme in the secondary literature is that surrogate endpoints moved more convincingly than patient-centred ones.

Outcome Domains at a Glance

Safety and Tolerability: What Studies Report

Safety is part of any benefit discussion because tolerability determines whether an agent is usable. The 2024 systematic review and network meta-analysis of pharmacotherapy for cancer cachexia assessed safety alongside efficacy across the drug classes studied in this indication (PMID 39225556). The 2022 drug profile of anamorelin for cancer cachexia covered its tolerability profile as part of the overall clinical characterisation (PMID 35274629), and the 2024 review of anamorelin in cancer anorexia-cachexia syndrome discussed safety considerations relevant to its clinical use (PMID 38771469).

Specific adverse-event rates are not reproduced here because they are not within the abstract scope of the verified sources listed below. Readers interested in the full safety characterisation should consult the primary trial publications and the prescribing information for the jurisdictions where anamorelin is approved.

Benefits People Search For That the Literature Does Not Support

Several claimed benefits circulate outside the oncology literature. Based on the verified sources on this page, the following are not supported:

• Athletic performance or body recomposition in healthy adults. The cited evidence base concerns cancer anorexia-cachexia syndrome (PMID 38771469), not healthy or athletic populations.
• Strength gains. Reviewers specifically identified functional endpoints as the area where the evidence fell short (PMID 28957883).
• Anti-tumour or survival-extending action. The network meta-analysis of cancer cachexia pharmacotherapy did not establish this for anamorelin (PMID 39225556).
• General anti-ageing or sarcopenia use outside oncology. The 2025 sarcopenia review in this set addressed gastrointestinal cancer populations specifically (PMID 41206817).

Where the Field Appears to Be Moving

Cachexia is increasingly described as multifactorial, and single-pathway agents have struggled. A 2026 mechanistic evaluation examined anti-GDF-15 antibody-based combination therapies as an approach to targeting cancer cachexia (PMID 42126170), reflecting interest in pathways beyond ghrelin signalling. A 2022 commentary on future prospects in cancer cachexia discussed similar directions (PMID 35851337), and the 2016 overview of clinical results in cachexia therapeutics had already noted the pattern of partial successes in the field (PMID 26974316).

Standardisation of endpoints is the other active thread. The 2024 systematic review of biomarker endpoints in cancer cachexia clinical trials, part of a wider cachexia endpoint series, examined how outcomes were selected and measured across trials (PMID 38783477), which bears directly on how future anamorelin-era results will be interpreted.

Summary of the Evidence Picture

Across the cited record, the pattern researchers reported was a compound with a reasonably consistent signal on body weight and lean body mass in cancer cachexia populations (PMID 35274629), appetite-related symptom outcomes discussed within the same trial programme (PMID 38771469), and an acknowledged shortfall on strength and function endpoints (PMID 28957883). Comparative synthesis across cachexia drugs remained inconclusive for patient-centred outcomes (PMID 39225556).

For background on the compound itself, mechanism, regulatory status and how it is categorised, see the related overview at /learn/anamorelin/. This page is educational and does not constitute medical advice; decisions about any therapy belong with a licensed physician who knows the individual case.

References

• Anamorelin for cancer cachexia (Drugs of Today, 2022)
• What is next after anamorelin? (Current Opinion in Supportive and Palliative Care, 2017)
• Anamorelin for the Treatment of Cancer Anorexia-Cachexia Syndrome (Current Oncology Reports, 2024)
• Sarcopenia in gastrointestinal cancers (International Journal of Clinical Oncology, 2025)
• Clinical results in cachexia therapeutics (Current Opinion in Clinical Nutrition and Metabolic Care, 2016)
• Effect of anamorelin on body weight in patients with gastric cancer-associated cachexia: an observational study (Gastric Cancer, 2025)
• Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series (Journal of Cachexia, Sarcopenia and Muscle, 2024)
• Efficacy and safety of pharmacotherapy for cancer cachexia: A systematic review and network meta-analysis (Cancer Medicine, 2024)
• Cancer Cachexia: One Step Ahead (Reviews on Recent Clinical Trials, 2015)
• Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC (Expert Opinion on Pharmacotherapy, 2015)
• [Future Prospects of Cancer Cachexia] (Gan To Kagaku Ryoho, 2022)
• Targeting Cancer Cachexia: A Mechanistic Evaluation of Anti-GDF-15 Antibody-Based Combination Therapies (Journal of Cachexia, Sarcopenia and Muscle, 2026)